Bigora Sian 4

What Happened

Bigora Sian, Chief Development Officer of Processa Pharmaceuticals, acquired 1,986 shares on 2026-04-30 at $2.69 per share, for a total reported cost of $5,342. The transaction is reported as a purchase (code P), which indicates an open-market or private purchase.

Key Details

• Transaction date and price: 2026-04-30, 1,986 shares at $2.69/share (total ~$5,342).
• Filing: Form 4 filed 2026-05-01 (period of report 2026-04-30) — filed one day after the trade, which appears timely under standard Form 4 rules.
• Shares owned after transaction: Not reported in the supplied transaction details.
• Footnotes/plans: No 10b5-1 plan, tax-withholding, or other footnotes were provided in the supplied data.

Context

Purchases by insiders are often watched by investors as a potential sign of confidence, but this purchase is relatively small (~$5.3K) and should be weighed with other information about the company and insider activity. No derivatives, exercises, or immediate sales were reported for this transaction.